Valuation: Ipsen

Market Cap 13.33B 15.21B 12.29B 11.51B 21.58B 1,434B 22.02B 148B 57.16B 709B 57.1B 55.85B 2,458B P/E 2026 *
15x
P/E 2027 * 14.7x
Enterprise Value 11.97B 13.65B 11.03B 10.33B 19.37B 1,288B 19.77B 133B 51.32B 637B 51.27B 50.15B 2,207B EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.45x
Free-Float
40.65%
Yield 2026 *
0.88%
Yield 2027 * 0.91%
1 day-1.29%
1 week+4.76%
Current month+3.48%
1 month-0.56%
3 months+7.14%
6 months+34.84%
Current year+35.30%
1 week 155.5
Extreme 155.5
162.7
1 month 150.6
Extreme 150.6
162.7
Current year 116.5
Extreme 116.5
172.7
1 year 101.3
Extreme 101.3
172.7
3 years 90.2
Extreme 90.2
172.7
5 years 77.76
Extreme 77.76
172.7
10 years 36.84
Extreme 36.84
172.7
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%+4.76% - - 15.16B
+7.13%+9.97%+51.94%+166.83% 1,006B
+3.99%+11.50%+67.53%+55.63% 589B
+4.20%+17.03%+35.63%+87.74% 430B
+0.99%+4.85%+27.93%+22.82% 331B
+1.82%+8.19%+41.15%+26.80% 288B
+0.22%+6.75%+31.51%+42.02% 285B
+0.73%+8.53%-26.22%-40.85% 213B
+1.56%+6.14%+28.38%+59.45% 190B
+3.26%+3.33%+18.83%+67.03% 154B
Average +1.73%+8.46%+30.74%+54.16% 387.31B
Weighted average by Cap. +2.24%+9.14%+40.20%+79.88%

Financials

2026 *2027 *
Net sales 4.25B 4.85B 3.92B 3.67B 6.88B 458B 7.03B 47.12B 18.23B 226B 18.22B 17.82B 784B 4.47B 5.1B 4.12B 3.86B 7.23B 481B 7.38B 49.52B 19.16B 238B 19.14B 18.72B 824B
Net income 923M 1.05B 851M 797M 1.49B 99.31B 1.52B 10.23B 3.96B 49.08B 3.95B 3.87B 170B 938M 1.07B 864M 809M 1.52B 101B 1.55B 10.39B 4.02B 49.86B 4.02B 3.93B 173B
Net Debt -1.36B -1.55B -1.26B -1.18B -2.2B -147B -2.25B -15.09B -5.84B -72.42B -5.83B -5.71B -251B -2.37B -2.71B -2.19B -2.05B -3.84B -255B -3.92B -26.28B -10.17B -126B -10.16B -9.94B -437B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
26/06/26 €160.60 -1.29%
25/06/26 €162.70 +0.31%
24/06/26 €162.20 +4.31%
23/06/26 €155.50 -0.06%
22/06/26 €155.60 +1.50%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
162.40EUR
Average target price
160.00EUR
Spread / Average Target
-1.48%

Quarterly revenue - Rate of surprise